Patents by Inventor Matityahu Fridkin
Matityahu Fridkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140121352Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: YORAM SHECHTER, MATITYAHU FRIDKIN, HAIM TSUBERY
-
Publication number: 20130116175Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: December 31, 2012Publication date: May 9, 2013Applicant: Yeda Research and Development Co., Ltd.Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8343910Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: August 12, 2009Date of Patent: January 1, 2013Assignee: Yeda Research Development Co., LtdInventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20120134977Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: June 1, 2010Publication date: May 31, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yoram Shechter, Matityahu Fridkin
-
Publication number: 20120045411Abstract: The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells.Type: ApplicationFiled: February 10, 2010Publication date: February 23, 2012Applicant: Yeda Research and Development Co., Ltd.Inventors: Tsvee Lapidot, Alexander Kalinkovich, Matityahu Fridkin
-
Patent number: 7960507Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 27, 2010Date of Patent: June 14, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas, Arthur Machlenkin, Esther Tzehoval
-
Patent number: 7906620Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: GrantFiled: July 28, 2003Date of Patent: March 15, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20100291127Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: July 27, 2010Publication date: November 18, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: LEA EISENBACH, BOAZ TIROSH, EREZ BAR-HAIM, ADRIAN PAZ, MATITYAHU FRIDKIN, CHERYL FITZER-ATTAS, ARTHUR MACHLENKIN, ESTHER TZEHOVAL
-
Patent number: 7795224Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: December 2, 2008Date of Patent: September 14, 2010Assignee: Yeda Research and Development Co., Ltd.Inventors: Lea Eisenbach, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20100041867Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: August 12, 2009Publication date: February 18, 2010Applicant: Yeda Reserch and Development Co., Ltd.Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 7585837Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: October 6, 2005Date of Patent: September 8, 2009Assignee: Yeda Research and Development Co. Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20090136462Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: December 2, 2008Publication date: May 28, 2009Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea EISENBACH, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Patent number: 7531629Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: March 29, 2006Date of Patent: May 12, 2009Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Adrian Paz, Matityahu Fridkin
-
Patent number: 7435716Abstract: Novel conjugates of bacterial outer membrane binding peptides, preferably having bacterial sensitization activity, and immune cells chemotactic peptides, and pharmaceutical compositions containing same useful in the treatment of bacteremia and/or septicemia following infection by gram negative bacteria administered alone or in combination with conventional antibiotics.Type: GrantFiled: January 16, 2002Date of Patent: October 14, 2008Assignees: Ramot At Tel Aviv University Ltd., Yeda Research and Development Co. Ltd.Inventors: Itzhak Ofek, Matityahu Fridkin, Haim Tsubery
-
Patent number: 7182945Abstract: A peptide corresponding to positions 62–71 of the sequence of human C-reactive protein (CRP) of the formula: Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71 and modifications thereof obtained by substitution, deletion, or addition of amino acids, amidation of the C-terminal or acylation of the N-terminal, are capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG) and can be used for the treatment of chronic inflammation conditions such as rheumatoid arthritis, pulmonary emphysema, cystic fibrosis, bronchitis, asthma and some acute respiratory distress syndrome.Type: GrantFiled: February 27, 2003Date of Patent: February 27, 2007Assignee: Yeda Research and Development Co. Ltd.Inventors: Matityahu Fridkin, Eran Yavin
-
Publication number: 20070027073Abstract: The invention provides a PYY agonist derivative of the formula: (X)n-Z, wherein X is a radical 9-fluorenylmethoxy-carbonyl (Fmoc) or 2-sulfo-9-fluorenyl-methoxycarbonyl (FMS), Z is the residue of a PYY agonist linked to the radical X through an amino or hydroxyl group, and n is 1 to 3, or a pharmaceutically acceptable salt thereof, for reducing food intake and treatment of a disease, condition or disorder that can be alleviated by reduction of food intake such as obesity, hypertension, dyslipidemia, cardiovascular risk, eating disorder, insulin-resistance, or diabetes mellitus.Type: ApplicationFiled: April 8, 2004Publication date: February 1, 2007Inventors: Menachem Rubinstein, Yoram Shechter, Matityahu Fridkin
-
Publication number: 20060263342Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: ApplicationFiled: July 28, 2003Publication date: November 23, 2006Applicant: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20060234927Abstract: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and/or treatment of skin ageing and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.Type: ApplicationFiled: February 21, 2006Publication date: October 19, 2006Applicants: Technion Research and Development Foundation Ltd., Yeda Research and Development Co., Ltd.Inventors: Moussa Youdim, Matityahu Fridkin, Hailin Zheng, Abraham Warshawsky, Rivka Warshawsky
-
Publication number: 20060194730Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20060171920Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: October 6, 2005Publication date: August 3, 2006Applicant: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery